Loading...
XCSE
BIOPOR
Market cap89mUSD
Sep 11, Last price  
1.17DKK
1D
-0.85%
1Q
-0.85%
Jan 2017
-44.29%
Name

Bioporto A/S

Chart & performance

D1W1MN
XCSE:BIOPOR chart
P/E
—
P/S
14.38
EPS
—
Div yield, %
—
Shrs. gr., 5y
20.28%
Rev. gr., 5y
11.67%
Revenues
40m
+11.16%
5,554,0008,340,0008,340,00011,008,00013,802,00018,584,00017,858,00016,625,00018,706,00020,383,00020,720,00025,155,00026,016,00026,622,00023,204,00024,254,00028,969,00030,958,00036,243,00040,287,000
Net income
-82m
L+20.33%
-16,985,000-15,246,000-14,264,000-16,078,000-14,300,000-14,906,000-14,700,000-20,623,000-12,926,000-10,732,000-22,800,000-32,243,000-38,048,000-69,642,000-61,562,000-57,113,000-75,923,000-56,328,000-68,243,000-82,117,000
CFO
-77m
L-7.80%
-13,456-14,129,000-13,717,000-13,286,000-13,379,000-13,606,000-15,280,000-16,640,000-16,138,000-16,574,000-19,660,000-29,399,000-38,009,000-60,164,000-35,616,000-64,577,000-52,485,000-55,456,000-83,583,000-77,066,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

BioPorto A/S is a Danish in-vitro diagnostics specialist, supplying biomarker tests, research tools, and antibodies to medical professionals and scientists worldwide, with operations across Europe, North America, and Asia. Among its offerings is the neutrophil gelatinase-associated lipocalin (NGAL) test, a precise quantitative particle-enhanced turbidimetric immunoassay designed for use on automated chemistry analyzers. The company further provides monoclonal antibodies essential for scientific, pharmaceutical, and clinical investigations. Additionally, BioPorto produces enzyme-linked immunosorbent assay (ELISA) kits and a versatile rapid assay device tailored for custom lateral flow assay development. Established in 1917, the company is headquartered in Hellerup, Denmark.

Key people

Thomas Magnussen
Chairman of the Board · since 2013
Peter Moerch Eriksen
Chief Executive Officer · since 2013
Jan Kuhlmann Andersen
Chief Operation Officer · since 2016
Finn Fjorder
Executive Vice President Sales · since 2013
Christopher Bird
Chief Medical Officer · since 2019
Michael Singer
Director · since 2019
URL
https://bioporto.com/
IPO date
Jan 02, 1985
Employees
Domiciled in
DK
Incorporated in
DK
Headquarters & legal address
Tuborg Havnevej 15, st.
Hellerup, 84 2900
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT